Compare · RVMD vs SOPH
RVMD vs SOPH
Side-by-side comparison of Revolution Medicines Inc. (RVMD) and SOPHiA GENETICS SA (SOPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RVMD and SOPH operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $31.57B, about 83.4x SOPH ($378.4M).
- Over the past year, RVMD is up 265.7% and SOPH is up 82.9% - RVMD leads by 182.8 points.
- SOPH has been more active in the news (12 items in the past 4 weeks vs 5 for RVMD).
- RVMD has more recent analyst coverage (25 ratings vs 13 for SOPH).
- Company
- Revolution Medicines Inc.
- SOPHiA GENETICS SA
- Price
- $148.49-0.48%
- $5.25+6.28%
- Market cap
- $31.57B
- $378.4M
- 1M return
- +4.07%
- -2.78%
- 1Y return
- +265.68%
- +82.93%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2021
- News (4w)
- 5
- 12
- Recent ratings
- 25
- 13
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
SOPHiA GENETICS SA
Sophia Genetics SA, a cloud-based software-as-a-service platform that enables healthcare institutions to get insights from their data. The company offers SOPHiA DDM for solid tumors. Sophia Genetics SA was founded in 2012 and is based in Saint-Sulpice, Switzerland.
Latest RVMD
- Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
- Officer Mancini Anthony exercised 3,121 shares at a strike of $33.62 and sold $480,611 worth of shares (3,121 units at $153.99) as part of a pre-agreed trading plan (SEC Form 4)
- Bernstein initiated coverage on Revolution Medicines with a new price target
- Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation
- Truist resumed coverage on Revolution Medicines with a new price target
- Amendment: SEC Form SCHEDULE 13G/A filed by Revolution Medicines Inc.
- Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
- SEC Form 10-Q filed by Revolution Medicines Inc.
- Revolution Medicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress
Latest SOPH
- Chief Financial Officer Cardoza George bought $99,000 worth of Ordinary Shares (20,000 units at $4.95), increasing direct ownership by 7% to 311,458 units (SEC Form 4)
- SEC Form 6-K filed by SOPHiA GENETICS SA
- SOPHiA GENETICS Signs Strategic Collaboration MOU with Leading Global Cancer Center
- Chief Medical Officer Menu Philippe sold $24,774 worth of Ordinary Shares (5,000 units at $4.95) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 250,780 units (SEC Form 4)
- President Muken Ross sold $3,501 worth of Ordinary Shares (761 units at $4.60) as part of a pre-agreed trading plan, decreasing direct ownership by 0.11% to 680,911 units (SEC Form 4) (tax liability)
- Chief Scientific Officer Xu Zhenyu sold $2,798 worth of Ordinary Shares (608 units at $4.60) as part of a pre-agreed trading plan, decreasing direct ownership by 0.10% to 626,280 units (SEC Form 4) to satisfy tax liability
- Chief Executive Officer Camblong Jurgi sold $20,658 worth of Ordinary Shares (4,486 units at $4.60) as part of a pre-agreed trading plan, decreasing direct ownership by 0.12% to 3,629,495 units (SEC Form 4) (withholding tax)
- Chief Medical Officer Menu Philippe sold $2,800 worth of Ordinary Shares (608 units at $4.61) as part of a pre-agreed trading plan, decreasing direct ownership by 0.24% to 255,780 units (SEC Form 4) (tax withholding)
- Chief Legal Officer Van Well Daan sold $3,149 worth of Ordinary Shares (684 units at $4.60) as part of a pre-agreed trading plan, decreasing direct ownership by 0.20% to 345,052 units (SEC Form 4) to satisfy tax liability
- Chief People Officer Valente Manuela sold $1,747 worth of Ordinary Shares (380 units at $4.60) as part of a pre-agreed trading plan, decreasing direct ownership by 0.18% to 214,691 units (SEC Form 4) (tax withholding)